1/17/2014 7:21:23 AM
Shareholders of Gentium SpA filed a case against the company's board in a bid to halt Jazz Pharmaceuticals Plc from acquiring it, Bloomberg reported. The shareholders claimed that the deal, valued at $1 billion is "hopelessly flawed." A biopharmaceutical firm, Gentium concentrates on discovering, researching and manufacturing therapies to treat and prevent a number of vascular diseases and cancer-related conditions. Jazz Pharmaceuticals, meanwhile, identifies, develops and commercializes products for narcolepsy, oncology, pain and psychiatry.
Help employers find you! Check out all the jobs and post your resume.
comments powered by